Posted in General 
July 29th, 2009

Inovio Biomedical Corporation (NYSE Amex: INO) shares are up more than 150 percent to $1.95 on 5 times average volume as of 10:15 a.m. Eastern. Traders are chasing the news reports this morning that its SynCon™ H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies. Inovio Biomedical is engaged in the design, development, and delivery of a new generation of DNA vaccines, focused on cancers and infectious diseases.

See BioHealthInvestor for full details.

Comments are closed